Abstracts tagged "spondyloarthritis"

Abstract Number: 0905 • ACR Convergence 2021
Artificial Neural Network for the Recognition of Active Inflammatory Changes Compatible with Axial Spondyloarthritis on Magnetic Resonance Imaging of Sacroiliac Joints
Denis Poddubnyy¹, Janis Vahldiek², Lisa Adams², Torsten Diekhoff², Fabian Proft², Mikhail Protopopov², Judith Rademacher², Valeria Rios Rodriguez², Murat Torgutalp², Stefan Niehues² and Keno Bressem², ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Active inflammatory changes in sacroiliac joints (SIJ) compatible with axial spondyloarthritis - axSpA (first of all, subchondral bone marrow edema – BME / osteitis)…
Abstract Number: 0935 • ACR Convergence 2021
Effects of Ixekizumab Treatment on Structural Changes in the Sacroiliac Joints Based on MRI Assessments at 16 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis
Walter Maksymowych¹, Xenofon Baraliakos², Robert Lambert³, Robert Landewé⁴, David Sandoval Calderon⁵, Hilde Carlier⁶, Jeffrey Lisse⁷, Xiaoqi Li⁵, Maja Hojnik⁵ and Mikkel Ostergaard⁸, ¹Department of Medicine, Division of Rheumatology at the University of Alberta, Alberta, Canada, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³University of Alberta, Edmonton, AB, Canada, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Brussels, Belgium, ⁷Eli Lilly and Company, Tucson, AZ, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: To evaluate the effect of treatment with ixekizumab versus placebo (PBO) on structural lesions in the sacroiliac joints (SIJ) at 16 weeks in patients…
Abstract Number: 1314 • ACR Convergence 2021
Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis
Haluk Cinaklı¹, Elif Ediboglu¹, Eda Otman Akat², Dilek Solmaz³, Gulay Alp¹, Esra Erpek¹, Sercan Gücenmez⁴, Mustafa Ozmen⁴ and Servet Akar³, ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²katip çelebi, izmir, Turkey, ³Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ⁴katip çelebi university, izmir, Turkey
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis and enthesitis may also occur. Acute…
Abstract Number: 1787 • ACR Convergence 2021
What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden: A Post Hoc Analysis of the ASAS-PerSpA International Study
Nelly Ziade¹, Joe Rassi², Bassel Elzorkany³, Clementina López Medina⁴, Sherif Gamal³, Sani Hlais⁵, Maxime Dougados⁶ and Xenofon Baraliakos⁷, ¹Rheumatology Department, Saint-Joseph Medical University and Hotel-Dieu de France Hospital, Beirut, Lebanon, ²Department of Orthopedic Surgery, Hotel-Dieu de France, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon, ³Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Department of Family Medicine, American University of Beirut/ Saint-Joseph University, Beirut, Lebanon, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Peripheral spondyloarthritis (pSpA) shows features that overlap with psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and other forms of SpA and is unsatisfactorily defined despite…
Abstract Number: 0059 • ACR Convergence 2021
Deep Immune Cell Profiling of Tissue Microenvironment Using Imaging Mass Cytometry in Psoriatic Disease
Lihi Eder¹, Stephane Caucheteux¹, Somi Afiuni², Adriana Krizova¹, James Limacher¹, Hartland Jackson¹ and Vincent Piguet¹, ¹University of Toronto, Toronto, ON, Canada, ²Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada
Background/Purpose: Cross talk between different cell types, such as T cell subsets and other immune cell populations, is important in psoriatic disease. Imaging Mass Cytometry…
Abstract Number: 0366 • ACR Convergence 2021
Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Souzi Makri⁴, Laura Christen⁵, José Correa-Fernández⁶, Sergio Sanz-Gomez⁶, Raj Mahapatra⁷, Carlos Jesús Delgado-Domínguez⁶ and Denis Poddubnyy⁸, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁷Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁸Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: AxSpA is associated with substantial negative consequences regarding work status and career prospects. The aim is to identify factors associated with barriers to job…
Abstract Number: 0384 • ACR Convergence 2021
A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
Rouhin Sen¹, Emmeline Kim², Elizabeth Cheng³, Kavya Ganuthula⁴, Meika Fang⁵, Gail Kerr⁶, Jessica Walsh⁷, Elizabeth Chang⁸, Siba Raychaudhuri⁹, Andreas Reimold¹⁰ and Liron Caplan¹¹, ¹University of Colorado School of Medicine/Rocky Mountain Regional Veterans Affairs Medical Center (VAMC), Denver, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rocky Mountain Regional VAMC, Aurora, CO, ⁴Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, ⁵David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, ⁶Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸Phoenix Veterans Affairs Medical Center (VAMC), Phoenix, AZ, ⁹Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ¹⁰University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ¹¹Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Biomarkers of disease activity/severity and imaging outcomes in axial spondyloarthritis (axSpA) remain a challenge. The most common relevant biomarker is the C-Reactive Protein (CRP),…
Abstract Number: 0907 • ACR Convergence 2021
Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients with Non-Radiographic Axial Apondyloarthritis
Stan Kieskamp¹, Rick Wilbrink², Freke Wink³, Reinhard Bos⁴, Hendrika Bootsma¹, Suzanne Arends¹ and Anneke Spoorenberg¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University of Groningen, Leeuwarden, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: In two years, approximately 10% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) progresses to ankylosing spondylitis (AS). There are no data available of more…
Abstract Number: 0936 • ACR Convergence 2021
Factors Associated with the Development of Anti-drug Antibodies to Tumour Necrosis Factor Inhibitors in Patients with Axial Spondyloarthritis; A Two Year Follow-up Study
Elif Ediboglu¹, Dilek Solmaz², Gokhan Kabadayi³, Mustafa Ozmen⁴, Kübra Kaya⁵, Muhammet Çınar⁶, Gökhan Sargın⁷, Gülen Hatemi⁸, Ömer Karadağ⁹, Gülay Kınıklı¹⁰, Onay Gercik¹¹, Umut Kalyoncu⁹, Sedat Yılmaz⁶, Taskın Şentürk⁷, Gokhan Keser¹², Figen Yargucu¹², Ayse Cefle¹³, Didem Kozacı⁵, Bünyamin Kısacık¹⁴ and Servet Akar², ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ³Cigli Education and Research Hospital, İzmir, Turkey, ⁴katip çelebi university, izmir, Turkey, ⁵Yıldırım Beyazit University, Ankara, Turkey, ⁶Gülhane Education and Research Hospital, Ankara, Turkey, ⁷Adnan Menderes University, Aydın, Turkey, ⁸Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, İstanbul, Turkey, ⁹Hacettepe University, Ankara, Turkey, ¹⁰Ankara University, Ankara, Turkey, ¹¹Izmir Katip Celebi University, Izmir, Turkey, ¹²Ege University, İzmir, Turkey, ¹³Kocaeli University, Kocaeli, Turkey, ¹⁴Gaziantep Medicalpark Hospital, Gaziantep, Turkey
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac joints and spine as well as peripheral joints and entheses. Tumour necrosis factor…
Abstract Number: 1316 • ACR Convergence 2021
Vitamin D Deficiency and Disease Activity in Patients with Spondyloarthritis
Maria Rato¹, Filipe Pinheiro¹, Salomé Garcia¹, Bruno Fernandes², Ana Martins¹, Daniela Oliveira¹, Frederico Martins³, Diogo Fonseca⁴, Alexandra Bernardo¹, Miguel Bernardes¹ and Lúcia Costa¹, ¹Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ²Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, ³Rheumatology Department, Centro Hospitalar Universitário do Algarve EPE, Algarve, Portugal, ⁴Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE, Gaia, Portugal
Background/Purpose: There are increasing data about vitamin D immunomodulatory potential in different rheumatologic disorders. Deficiency of vitamin D is frequent in patients with spondyloarthritis (SpA)…
Abstract Number: 1788 • ACR Convergence 2021
Improving Care and Capacity Through Capturing and Recording Patient Reported Outcomes with Digital Solutions in Spondyloarthritis
Antoni Chan¹, Kathryn Rigler¹ and Liz van Rossen², ¹Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ²East Kent NHS Foundation Trust, Kent, United Kingdom
Background/Purpose: Patient-reported outcomes (PROs) have always been at the forefront for the assessment of spondyloarthritis (SpA) which includes axial Spa (axSpA) and psoriatic arthritis (PsA).…
Abstract Number: 0062 • ACR Convergence 2021
Axial Spondyloarthritis and Its Related Immune-Mediated Diseases Share a Gut Microbiome Signature Besides Their Own Distinctive Profile
Valeria Rios Rodriguez¹, Morgan Essex², Judith Rademacher¹, Fabian Proft¹, Ulrike Löber², Lajos marko², Uwe Pleyer³, Britta Siegmund⁴, Denis Poddubnyy⁵ and Sofia Forslund⁶, ¹Charité University Medicine Berlin, Berlin, Germany, ²Experimental and Clinical Research Center of the MDC and Charité Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Department of Ophthalmology, Berlin, Germany, ⁴Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin. Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁵Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁶Experimental an dclinical Research Center of the MDC and Charité Berlin, Berlin, Germany
Background/Purpose: Deep profiling of gut microbiota may reveal new pathways of how SpA and its related diseases such as Crohn’s disease (CD) and acute anterior…
Abstract Number: 0367 • ACR Convergence 2021
Can Belonging to an AxSpA Patient Organization Be Associated with Benefits to Its Members? Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Souzi Makri², Denis Poddubnyy³, Christine Bundy⁴, Laura Christen⁵, Sergio Sanz-Gomez⁶, José Correa-Fernández⁶, Raj Mahapatra⁷, Carlos Jesús Delgado-Domínguez⁶ and Victoria Navarro-Compán⁸, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ³Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁴Cardiff University, Cardiff, Wales, United Kingdom, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁷Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁸Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: Patient organizations (POs) provide education and support services aimed to improve the quality of life of axSpA patients. This analysis aims to identify factors…
Abstract Number: 0450 • ACR Convergence 2021
Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis
Mark Hwang¹, Minjae Lee², Lianne Gensler³, Matthew Brown⁴, Amirali Tahanan⁵, Mohammad Rahbar⁶, Theresa Hunter⁷, Mingyan Shan⁸, Mariko Ishimori⁹, John Reveille¹⁰, Michael Weisman¹¹ and Thomas Learch¹², ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²UT Southwestern, Dallas, TX, ³Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴King's College London, London, United Kingdom, ⁵McGovern Medical School, Houston, TX, ⁶Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, ⁷Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Cedars-Sinai Health System, Los Angeles, CA, ¹⁰Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ¹¹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹²Cedars-Sinai, Los Angeles, CA
Background/Purpose: Little is known about the natural history of spinal disease in Ankylosing Spondylitis (AS). Our objective was to identify distinct patterns of change in…
Abstract Number: 0910 • ACR Convergence 2021
The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
Jean Liew¹, S. Reza Jafarzadeh², Maureen Dubreuil³, Susan Heckbert⁴, Stephen Mooney⁴, Matthew Brown⁵, Mariko Ishimori⁶, John Reveille⁷, Michael Ward⁸, Michael Weisman⁹ and Lianne Gensler¹⁰, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine/ VA Boston, Boston, MA, ⁴University of Washington, Seattle, WA, ⁵King's College London, London, United Kingdom, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁸Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States, Rockville, MD, ⁹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) is associated with greater cardiovascular (CV) risk than in the general population. The impact of tumor necrosis factor inhibitors (TNFi) on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].